文献速递艾滋病与性传播感染

法国2016-18年全国队列:PrEP启动后HIV检测依从性与HIV发病率

PrEP monitoring and HIV incidence after PrEP initiation in France: 2016-18 nationwide cohort study.
PubMed 文献 · J Antimicrob Chemother · 2021-01-01

该历史性队列研究利用法国国家健康数据库纳入2016年1月至2018年6月启动口服PrEP的9893名成人,随访至2018年12月31日。结果显示启动后1个月HIV检测率为64%,后续检测率超过81%并保持稳定;无处方续配者检测依从性低,而最后处方由医院医生开具者检测依从性高。

要点

  • 口服PrEP使用者启动后1个月HIV检测率为64%,后续检测率超过81%且稳定。
  • PrEP使用者HIV发病率为0.19例/100人年(99%CI 0.12-0.30)。
  • 无处方续配者HIV检测依从性低(OR 0.15),医院医生处方者依从性高(OR 2.03)。

核心结论

  • 研究证实PrEP使用者对HIV检测有良好依从性及PrEP的有效性,有助于降低法国HIV发病率。
  • 法国国家健康数据库可作为PrEP使用者流行病学监测的自动化工具。

研究设计与样本

  • 历史性队列研究,纳入2016年1月1日至2018年6月30日法国所有启动口服PrEP的成人,共9893人。
  • 随访从首次PrEP发药至2018年12月31日,中位随访551天(IQR 350-769)。
  • 使用广义线性混合模型分析PrEP随访中HIV检测依从性的相关因素。

主要发现

  • 启动PrEP后1个月首次HIV检测由64%使用者完成,后续检测率超过81%并随时间保持稳定。
  • 无处方续配者HIV检测依从性更低(OR 0.15;99%CI 0.12-0.20)。
  • 最后处方由医院医生开具者HIV检测依从性更高(OR 2.03;99%CI 1.69-2.45)。

临床怎么用

  • 应关注无处方续配的PrEP使用者,其HIV检测依从性较低,需加强随访提醒。
  • 医院医生参与处方可能有助于提高PrEP随访中的HIV检测依从性。
  • 可利用国家健康数据库自动化监测PrEP使用者的HIV检测和感染情况。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clinical trials have demonstrated that oral pre-exposure prophylaxis (PrEP) has high efficacy in preventing HIV transmission. In many countries, HIV testing is recommended prior to PrEP initiation, 1 month after and quarterly thereafter. We assessed the uptake of HIV testing and estimated the incidence of HIV infections after oral PrEP initiation, by using the French national health database (SNDS). METHODS: A historic cohort study included every adult person who started oral PrEP between 1 January 2016 and 30 June 2018 in France. HIV infection was tracked in the follow-up, from first PrEP dispensation up to 31 December 2018. Factors associated with adherence to HIV testing in PrEP follow-up were analysed using a generalized linear mixed model. RESULTS: PrEP users (9893) were followed for a median duration of 551 days (IQR 350-769). The first HIV test, 1 month after PrEP initiation, was performed by 64% of users. For subsequent tests, this rate exceeded 81% and remained stable over time. HIV testing was lower among PrEP users without prescription refill (OR 0.15; 99% CI 0.12-0.20), but higher if the last prescription was made by a hospital practitioner (OR 2.03; 99% CI 1.69-2.45). Twenty-nine HIV infections were identified, leading to an incidence of 0.19 cases per 100 person-years (99% CI 0.12-0.30). CONCLUSIONS: We confirmed good adherence to HIV testing and efficacy of PrEP in users, which should help in decreasing HIV incidence in France. This study also revealed that SNDS could be a powerful automated tool for the epidemiological monitoring of PrEP users.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Tassi MF, Laurent E, Gras G, et al. PrEP monitoring and HIV incidence after PrEP initiation in France: 2016-18 nationwide cohort study. J Antimicrob Chemother. 2021. PMID: 34293116. doi:10.1093/jac/dkab263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。